Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung Cancer.
Meng-Chin HoYing-Shan ChungYu-Ching LinMing-Szu HungYu-Hung FangPublished in: OncoTargets and therapy (2022)
The concurrent use of PPIs was associated with lower OS in patients with EGFR-mutant lung cancer under the first-line afatinib treatment but not associated with TTF.